Delivery Order SPE2DB22D3016-SPE2DB25FAUS2
Award Date 4/24/25
Potential Completion Date 5/15/25
Potential Value $137K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a $12,019.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. The contract was competitively awarded without set-aside provisions and carries an ultimate completion date of September 18, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency has awarded a delivery order valued at $120,192.80 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of May 15, 2025. The awardee, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,154.24 to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 24, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. Ocrevus is a monoclonal antibody therapeutic used to treat multiple sclerosis,...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 18, 2025. The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 9, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed price delivery order with an ultimate completion date of June 24, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $12,019.28 delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 12, 2025, and performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $48,077.16 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the critical role AmerisourceBergen plays in supplying...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a contract ceiling value of $43,178.96 under firm fixed price terms. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 16, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product used in the treatment of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed price contract, awarded on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....